Allen Capital Group LLC trimmed its position in Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 7.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,660 shares of the medical instruments supplier's stock after selling 130 shares during the period. Allen Capital Group LLC's holdings in Becton, Dickinson and were worth $370,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Congress Wealth Management LLC DE increased its stake in Becton, Dickinson and by 8.3% during the 3rd quarter. Congress Wealth Management LLC DE now owns 1,393 shares of the medical instruments supplier's stock worth $310,000 after purchasing an additional 107 shares in the last quarter. Resources Investment Advisors LLC. increased its stake in Becton, Dickinson and by 9.2% during the 3rd quarter. Resources Investment Advisors LLC. now owns 2,097 shares of the medical instruments supplier's stock worth $467,000 after purchasing an additional 176 shares in the last quarter. Vicus Capital increased its stake in Becton, Dickinson and by 5.2% during the 3rd quarter. Vicus Capital now owns 999 shares of the medical instruments supplier's stock worth $223,000 after purchasing an additional 49 shares in the last quarter. Old North State Trust LLC increased its stake in Becton, Dickinson and by 125,000.0% during the 3rd quarter. Old North State Trust LLC now owns 1,251 shares of the medical instruments supplier's stock worth $279,000 after purchasing an additional 1,250 shares in the last quarter. Finally, 9258 Wealth Management LLC increased its stake in Becton, Dickinson and by 5.4% during the 3rd quarter. 9258 Wealth Management LLC now owns 2,415 shares of the medical instruments supplier's stock worth $538,000 after purchasing an additional 124 shares in the last quarter. 87.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and

In other Becton, Dickinson and news, EVP Richard Byrd sold 1,421 shares of the firm's stock in a transaction on Friday, February 3rd. The stock was sold at an average price of $248.60, for a total transaction of $353,260.60. Following the completion of the sale, the executive vice president now owns 4,119 shares of the company's stock, valued at approximately $1,023,983.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.31% of the company's stock.

Becton, Dickinson and Price Performance

Becton, Dickinson and (NYSE:BDX – Get Rating) last released its earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.98 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.30. Becton, Dickinson and had a net margin of 8.47% and a return on equity of 13.52%. The business had revenue of $4.59 billion during the quarter, compared to analysts' expectations of $4.59 billion. During the same period last year, the business earned $3.64 earnings per share. The firm's revenue was down 2.8% on a year-over-year basis. On average, research analysts expect that Becton, Dickinson and Company will post 12.12 EPS for the current fiscal year.

Becton, Dickinson and Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 31st. Shareholders of record on Friday, March 10th will be issued a dividend of $0.91 per share. This represents a $3.64 annualized dividend and a yield of 1.46%. The ex-dividend date is Thursday, March 9th. Becton, Dickinson and's dividend payout ratio is 68.68%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on BDX. StockNews.com raised Becton, Dickinson and from a "hold" rating to a "buy" rating in a research note on Friday. Piper Sandler raised their price target on shares of Becton, Dickinson and from $245.00 to $260.00 and gave the stock a "neutral" rating in a research note on Thursday, February 2nd. The Goldman Sachs Group decreased their price target on shares of Becton, Dickinson and from $319.00 to $272.00 and set a "buy" rating for the company in a research note on Wednesday, November 23rd. Cowen decreased their price target on shares of Becton, Dickinson and to $255.00 in a research note on Wednesday, November 16th. Finally, Evercore ISI decreased their price target on shares of Becton, Dickinson and to $270.00 in a research note on Wednesday, November 16th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $275.70.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.

Further Reading

• Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
• Anhui Conch: Opportunity With Cement Solid Cash Flows
• Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
• Is Biotech Immunocore About To Make A 25% Price Move?
• Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
• Can Cummins Power To A New High?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Get Rating).

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.